75 related articles for article (PubMed ID: 20947165)
1. On the assessment of dasatinib-induced autophagy in CLL.
Krause G; Hallek M
Leuk Res; 2011 Jan; 35(1):137-8. PubMed ID: 20947165
[No Abstract] [Full Text] [Related]
2. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Amrein L; Soulières D; Johnston JB; Aloyz R
Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
[TBL] [Abstract][Full Text] [Related]
3. The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.
Pitini VV
Leuk Res; 2011 Jan; 35(1):32-3. PubMed ID: 20674019
[No Abstract] [Full Text] [Related]
4. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
[No Abstract] [Full Text] [Related]
6. Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.
Russwurm G; Heinsch M; Radkowski R; Erlemann R; Aul C; Haase S; Giagounidis A
Blood; 2010 Oct; 116(14):2617-8. PubMed ID: 20930084
[No Abstract] [Full Text] [Related]
7. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
D'Arena G; Gemei M; Luciano L; D'Auria F; Deaglio S; Statuto T; Bianchino G; Grieco V; Mansueto G; Guariglia R; Pietrantuono G; Martorelli MC; Villani O; Del Vecchio L; Musto P
J Clin Oncol; 2012 Nov; 30(32):e327-30. PubMed ID: 23008321
[No Abstract] [Full Text] [Related]
8. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Amrein PC; Attar EC; Takvorian T; Hochberg EP; Ballen KK; Leahy KM; Fisher DC; Lacasce AS; Jacobsen ED; Armand P; Hasserjian RP; Werner L; Neuberg D; Brown JR
Clin Cancer Res; 2011 May; 17(9):2977-86. PubMed ID: 21402714
[TBL] [Abstract][Full Text] [Related]
9. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Secchiero P; Melloni E; Voltan R; Norcio A; Celeghini C; Zauli G
Br J Haematol; 2012 May; 157(4):510-4. PubMed ID: 22313359
[No Abstract] [Full Text] [Related]
10. [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Hattori H; Kuwayama M; Kotake T; Karasuno T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):333-6. PubMed ID: 21368508
[TBL] [Abstract][Full Text] [Related]
11. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
Serpa M; Bendit I; Seguro F; Xavier F; Cavalcante M; Steinbaum D; Nardinelli L; Aldred VL; de Paula HM; Dorlhiac-Llacer PE
Acta Haematol; 2010; 124(2):105-9. PubMed ID: 20720403
[TBL] [Abstract][Full Text] [Related]
12. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Tiribelli M; Latagliata R; Luciano L; Castagnetti F; Gozzini A; Cambrin GR; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Montefusco E; Fava C; Fanin R; Pane F; Rosti G; Breccia M; Alimena G; Vigneri P
Ann Hematol; 2013 Jan; 92(2):179-83. PubMed ID: 23053188
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
14. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
15. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
16. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
[No Abstract] [Full Text] [Related]
17. Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Travis J
Science; 2004 Jul; 305(5682):319-21. PubMed ID: 15256643
[No Abstract] [Full Text] [Related]
18. Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate.
Yoon JY; Kumar R; Aloyz R; Johnston JB
Leuk Res; 2011 Sep; 35(9):e179-80. PubMed ID: 21802141
[No Abstract] [Full Text] [Related]
19. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.
Chow KU; Nowak D; Hofmann W; Schneider B; Hofmann WK
Leukemia; 2005 Jun; 19(6):1103-5; author reply 1105-6; discussion 1106-7. PubMed ID: 15815724
[No Abstract] [Full Text] [Related]
20. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Valent JN; Schiffer CA
Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
